Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography

BackgroundFluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been widely used for the diagnosis of pancreatic cancer. Because autoimmune pancreatitis is easily misdiagnosed as pancreatic cancer and can be tested for by FDG-PET analysis based on the presence of suspected pancreatic cancer, we attempted to clarify the differences in FDG-PET findings between the two conditions.MethodsWe compared FDG-PET findings between 15 patients with autoimmune pancreatitis and 26 patients with pancreatic cancer. The findings were evaluated visually or semiquantitatively using the maximum standardized uptake value and the accumulation pattern of FDG.ResultsFDG uptake was found in all 15 patients with autoimmune pancreatitis, whereas it was found in 19 of 26 patients (73.1%) with pancreatic cancer. An accumulation pattern characterized by nodular shapes was significantly more frequent in pancreatic cancer, whereas a longitudinal shape indicated autoimmune pancreatitis. Heterogeneous accumulation was found in almost all cases of autoimmune pancreatitis, whereas homogeneous accumulation was found in pancreatic cancer. Significantly more cases of pancreatic cancer showed solitary localization, whereas multiple localization in the pancreas favored the presence of autoimmune pancreatitis. FDG uptake by the hilar lymph node was significantly more frequent in autoimmune pancreatitis than in pancreatic cancer, and uptake by the lachrymal gland, salivary gland, biliary duct, retroperitoneal space, and prostate were seen only in autoimmune pancreatitis.ConclusionsFDG-PET is a useful tool for differentiating autoimmune pancreatitis from suspected pancreatic cancer, if the accumulation pattern and extrapancreatic involvement are considered. IgG4 measurement and other current image tests can further confirm the diagnosis.

[1]  S. Kawa,et al.  Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis , 2007, Journal of Gastroenterology.

[2]  S. Kawa,et al.  Characteristic Pancreatic Duct Appearance in Autoimmune Chronic Pancreatitis: A Case Report and Review of the Japanese Literature , 1998, American Journal of Gastroenterology.

[3]  Ludwig G. Strauss,et al.  Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.

[4]  S. Kawa,et al.  Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis , 2002, The Lancet.

[5]  M. Schäfer,et al.  Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness , 2005, Annals of surgery.

[6]  Brady K. Huang,et al.  Pancreatic pseudocyst observed on F-18 FDG PET imaging. , 2005, Clinical nuclear medicine.

[7]  B. Diamond,et al.  Autoimmune diseases , 2000, Bone Marrow Transplantation.

[8]  H. Sakahara,et al.  Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas , 2000, Cancer.

[9]  H. Sakai,et al.  Autoimmune Pancreatitis as a New Clinical Entity (Three Cases of Autoimmune Pancreatitis with Effective Steroid Therapy) , 1997, Digestive Diseases and Sciences.

[10]  G. Glatting,et al.  F-18 Fluorodeoxyglucose (FDG) and C-Reactive Protein (CRP). , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[11]  濱野 英明 High serum IgG4 concentrations in patients with sclerosing pancreatitis , 2002 .

[12]  T. Saga,et al.  Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) —Usefulness and limitations in “clinical reality”— , 2003, Annals of nuclear medicine.

[13]  S. Kawa,et al.  ERCP features in 27 patients with autoimmune pancreatitis. , 2002, Gastrointestinal endoscopy.

[14]  F. Chierichetti,et al.  F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: A prospective study , 2007, Journal of Gastrointestinal Surgery.

[15]  John L. Cameron,et al.  Pancreaticoduodenectomy (Whipple Resections) in Patients Without Malignancy: Are They All `Chronic Pancreatitis'? , 2003, The American journal of surgical pathology.

[16]  S. Hauptmann,et al.  F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. , 1994, Radiology.

[17]  E. Nitzsche,et al.  Evaluation of positron emission tomography with 2‐[18F]fluoro‐2‐deoxy‐D‐glucose for the differentiation of chronic pancreatitis and pancreatic cancer , 1999, The British journal of surgery.

[18]  O. Sabri,et al.  Fluorine-18 fluorodeoxyglucose positron mission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases , 1997, European Journal of Nuclear Medicine.

[19]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  T. Shimosegawa,et al.  Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal , 2006, Journal of Gastroenterology.

[21]  P. Shreve Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease , 1998, European Journal of Nuclear Medicine.

[22]  S. Kawa,et al.  CHAPTER 56 – Pancreatitis , 2006 .

[23]  K. Shiratori,et al.  Chronic pancreatitis caused by an autoimmune abnormality , 1995, Digestive Diseases and Sciences.

[24]  Higashi,et al.  Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings , 1999, Clinical nuclear medicine.

[25]  M. Kadoya,et al.  Hilar and Pancreatic Gallium-67 Accumulation is Characteristic Feature of Autoimmune Pancreatitis , 2003, Pancreas.

[26]  H. Sakahara,et al.  FDG-PET of autoimmune-related pancreatitis: preliminary results , 2000, European Journal of Nuclear Medicine.

[27]  W. Chapman,et al.  Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  M. Nagino,et al.  Intense PET signal in the degenerative necrosis superimposed on chronic pancreatitis. , 2005, Pancreas.

[29]  J. Drebin Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-effectiveness , 2006 .

[30]  N. Rose Autoimmune diseases. , 1981, Scientific American.

[31]  W. Oyen,et al.  FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Y. Yonekura,et al.  Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. , 1995, Radiology.

[33]  A. Luxen,et al.  Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.